Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Palo Alto and invests broadly across healthcare. Bryan is currently Chairman of the Board of Directors of Castlight Health (NYSE: CSLT), Ironwood Pharmaceuticals (NASDAQ: IRWD), Achaogen (NASDAQ: AKAO) and Kyruus. He also serves on the Board of 10X Genomics, Doctor on Demand, Grand Rounds, Intarcia, and Zeltiq (NASDAQ: ZLTQ), and is a Board observer at CloudFlare. Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), CodeRyte (acquired by 3M), Ikaria (acquired by Mallinkrodt), Illumina (NASDAQ: ILMN), and Sirna Therapeutics (acquired by Merck). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has ranked on Forbes’ Midas List eight times, 2008 – 2016.
Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.